Articles On Neuren Pharmaceuticals (ASX:NEU)

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a very positive note. At the time of writing, the benchmark index is up 1.45% to 7,792.6 points. Four ASX shares that have failed to follow the market...

Neuren (ASX:NEU) was the biggest faller in lunchtime trades on Friday after announcing some children were “minimally improved” in phase 2 of a trial treating children with Angelman syndrome. Shares were down -6.2% to just above $16.00ea...

Neuren shows promise in Angelman drug but shares down 7pc Avita aims for profitability by Q3 FY25 IDT lands $2.5-$4m mRNA contract with Sanofi   Neuren’s Angelman drug shows promise Market darling Neuren Pharmaceuticals (ASX:NEU) has just...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares have returned from their trading halt with an almighty thud. In morning trade, the pharmaceuticals company's shares are down 9% to $15.51. This compares unfavourably to the performance of the ASX...

The S&P/ASX 200 Index (ASX: XJO) comprises 11 market sectors, and the outperformer over the past decade may surprise you. It's not the flashy tech sector, nor the sectors home to the mega-miners or the Big Four bank shares. I...

With recent market volatility, prudent investors in ASX shares may be finding some relief. The uncertainty ahead, however, leaves many questioning what to expect next. While some retail investors have faced challenges, large institutional i...

Prudent investors in ASX shares will no doubt be breathing easier on Wednesday following the recent market volatility. However, visibility on what's next is not clear. It was Roman author Pliny the Elder who wrote "In wine, there is trut...

As the market whipsaws away this week, one ASX 200 healthcare share is on ice on Wednesday. Neuren Pharmaceuticals Ltd (ASX: NEU) requested the trading halt pending an announcement on one of its clinical programs. The business also r...

If you want to give your portfolio a boost, then it could be worth looking at Neuren Pharmaceuticals Ltd (ASX: NEU) shares. That's because one leading broker is tipping the ASX stock to rise over 60% from current levels. What is the broker...

Recent evaluations have spotlighted three ASX 200 shares that present notable opportunities for investors seeking substantial returns. These shares are garnering significant interest due to their strong growth potential and strategic positi...

Brokers have been running the rule over a large number of ASX 200 shares in recent weeks. Three shares that are highly rated and feature on best idea lists are named below. Here's why they could be great options: Neuren Pharmaceuticals Ltd...

  Neurotech reports positive results from extension phase of Phase 1/2 trial of NTI164 to treat Rett Syndrome NTI164 is first broad-spectrum cannabinoid drug therapy to show significant clinical improvement in Rett Syndrome patients All 14...

ASX health stocks rise 2% in past five days as broader markets lift 0.6% Morgans upgrades disinfectant device maker Nanosonics after positive trading update  Neuren receives rare paediatric disease designation from FDA for NNZ-2591 in Phel...

Neuren’s NNZ-2591 receives a Rare Pediatric Disease Designation from US FDA This could lead to a Priority Review Voucher if drug is approved Neuren is also preparing for a key FDA meeting, building on positive trial results    Neuren Phar...

Neuren’s NNZ-2591 receives a Rare Pediatric Disease Designation from US FDA This could lead to a Priority Review Voucher if drug is approved Neuren is also preparing for a key FDA meeting, building on positive trial results    Neuren Phar...

The S&P/ASX 200 Index (ASX: XJO) enjoyed another strong session this Wednesday, ploughing further into 8,000-point territory and resetting its all-time record...

Following Monday's market euphoria and fresh all-time highs, it was only natural for the S&P/ASX 200 Index (ASX: XJO) to experience a bit of a correction on Tuesday. Indeed, that's precisely what transpired, with the ASX 200 slipping by...

After yesterday's market euphoria and fresh all-time highs, it was only natural that the S&P/ASX 200 Index (ASX: XJO) endured a bit of a jolt back to earth this...

The 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference likely to attract institutional and high net worth WA investors  Day one focus on new opportunities, finding the next blockbuster drug and re...

Fortunately for growth investors, there are a lot of quality options for them to choose from on the Australian share market. Two ASX 200 growth shares that have been rated as top buys by brokers are listed below. Here's what they are saying...

If you were invested in ASX 200 shares vs. property in FY24 then you probably did pretty well. The S&P/ASX 200 Index (ASX: XJO) rose by 7.83% in FY24, and if we add dividends on top, the total return was a median 12.1%. Meanwhil...

If you're in the market for some new ASX 200 shares in July, then it could be worth listening to what analysts at Bell Potter are saying. That's because they have just revealed their favoured picks for the month ahead. Three on its list t...

In this article, we examine the best ASX 200 healthcare shares of FY24 based on share price growth. Here are the best performers, according to data from S & P Global Market Intelligence. The top 3 ASX 200 healthcare shares of FY2...

When we compare the capital growth of ASX 200 shares vs. property in FY24, bricks and mortar comes out on top… but only just. The S&P/ASX 200 Index (ASX: XJO) rose from a closing value of 7,203.3 points on the last trading day of FY...

If you are lucky enough to have $10,000 burning a hole in your pocket, it could be worth putting it to work in the share market. After all, over the long term, the share market has generated an average return of approximately 10% per annum....

A new financial year is on the horizon, so what better time to make some new additions to your investment portfolio. But which ASX 200 stocks could be buys? Let's take a look at three best buys for FY 2025 according to analysts at Bell Pott...

It was a decent end to what was a tough trading week for ASX shares and the S&P/ASX 200 Index (ASX: XJO) this Friday. After suffering a few drops this week, investors turne...

ASX health stocks rise in past five days, despite May uptick in inflation  Healius downgrades guidance for FY24, citing inflationary pressures Immutep falls despite positive results from Phase 2 trial in first line head and neck cancer He...

It was an unpleasant Wednesday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares this hump day. After enjoying a strong session yesterday, investors reversed course to...

I joined Adam Keily on the ‘Equity Mates’ podcast to discuss eight small-cap stocks, share my insights on their performance and answer whether I would buy or sell them. In this episode, we delve into the factors influencing each company pro...

Vinay Ranjan from Airlie Funds Management says investors should ignore industry predictions for where ASX 200 shares might go in the new financial year and instead simply focus on buying quality companies. Ranjan says attempting to profi...

ASX 200 healthcare stock Neuren Pharmaceuticals Ltd (ASX: NEU) has posted impressive gains over the past year but one director appears to still see value in today's share price. Neuren shares closed the session on Thursday at $19.31, up...

Looking to invest in an ASX biotech share with the potential to become the next Telix Pharmaceuticals Ltd (ASX: TLX)? You're not alone! The S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company has been going from strength to st...

ASX health stocks fall in past five days in line with broader markets as investors spooked by hotter than expected inflation Dimerix up 33% for week after inking second exclusive license deal for commercialisation of its Phase 3 kidney dis...

If you want to give your investment portfolio a nice boost, then it could be worth considering the ASX shares listed below. That's because they have been named as buys and tipped to rise materially from current levels. Here's what you need...

The ASX200 didn’t seem to be able to recover from the CPI inflation data (April) read – showing a rise to 3.6 per cent – which was hotter than many had forecast. The index lost more than 1.15 per cent – all sectors were down with Consume...

The S&P/ASX 200 Index (ASX: XJO) is having a very tough session on Wednesday. In response to the release of a hotter than expected inflation reading, the benchmark index is down 1.35% to 7,661.5 points. Four ASX shares that are falling...

Neuren Pharmaceuticals (ASX:NEU) has reported positive results from a Phase 2 trial of NNZ-2591 in children with Pitt-Hopkins syndrome.

ASX biotech shares have been showing significant signs of momentum lately. Exciting clinical trial results and strong investor interest are propelling the sector forward. Plenty of upcoming catalysts and company-specific developments could...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price was in fine form on Monday. The ASX 200 pharma stock ended the day almost 16% higher at $23.97. This means that Neuren Pharmaceuticals' shares are now up 78% since this time last year. I...

On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week in a very positive fashion. The benchmark index rose 0.8% to 7,788.3 points. Will the market be able to build on this on Tuesday? Here are five things to watch: ASX 200 expec...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a strong start to the trading week this Monday, turning things around from the sour end to last week. The ASX 200 appeared well-rested after the weeken...

ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on  Rare Earths find at the Tundulu project in Malawi   Aussie shares rebounded pretty much across the boa...

The S&P/ASX 200 Index (ASX: XJO) is having a strong start to the week. In afternoon trade, the benchmark index is up 0.8% to 7,786.8 points. Four ASX shares that are rising more than most today are listed below. Here's why they are ra...

The S&P/ASX 200 Index (ASX: XJO) is up a very healthy 0.8% today, but this ASX 200  healthcare share is leaving those gains wanting. Shares in the biopharmaceutical company closed on Wednesday trading for $20.71. The stock then...

Last Monday marked Clinical Trials Day, when the world’s healing profession celebrated the work of Royal Navy surgeon James Lind. The medical mariner was credited with carrying out the world’s first placebo-controlled clinical trial in 1747...

Xero and Nvidia buoyed Tech, while BHP dragged Mining Gold stocks were the worst performing miners today New tensions over China’s drills near Taiwan   The benchmark ASX 200 index was down about -0.50% on Thursday. Xero’s (ASX:XRO) 10% ju...

One of the highest growth ASX 200 healthcare stocks on the market went into a trading halt on Thursday. Neuren Pharmaceuticals Ltd (ASX: NEU) requested the trading halt before the market open today. The company said it wanted time t...

Do you remember how the COVID-19 market crash began, with ASX 200 shares plummeting almost 700 points in just five trading days? Oh, the shivers up my spine! And that was just the start of it, too. ASX 200 shares vs. property during...

I really like being gifted the data drops every month or so from the growing family of madly convenient broker platforms. I am also a huge fan of the ‘democratisation’ of stuff. These trading app-platform-thingys are a fine example. No long...